Immune checkpoint inhibitor induced autoimmune encephalitis in a patient with metastatic melanoma

Abstract

Background: Immune checkpoint inhibitors have changed the therapeutic milieu for patients with metastatic melanoma. However, their use may promote autoimmunity in virtually any organ in the body due to the blockade of intrinsic immune down regulators such as cytotoxic T-lymphocyte antigen- 4 (CTLA-4), programmed cell death 1 (PD1) or its ligand (PDL1). Immune mediated adverse neurological events are rare with these agents, however, and are seen in < 1% of treated patients. We report a patient with immune checkpoint inhibitor associated autoimmune encephalitis, with complete clinical recovery after treatment.

Case Report: A 49-year-old female with metastatic melanoma currently on nivolumab therapy but recently on ipilimumab/nivolumab combined therapy presented with a new headache. She also reported associated confusion, loss of balance, personality changes and language difficulty. Magnetic resonance imaging of the brain did not reveal any evidence of metastasis, infarct, meningitis, or encephalitis. Lumbar puncture revealed an elevated protein level and pleocytosis, with a normal glucose level. She was started on empiric glucocorticoid therapy with a presumptive diagnosis of immune checkpoint inhibitor associated autoimmune encephalitis. She improved considerably by day 3 of treatment with complete resolution of neurological symptoms by day 5.

Conclusion: Immune checkpoint inhibitors are increasingly important in cancer immunotherapy as they can cause sustained remissions in patients with metastatic melanoma and other malignancies. Because these drugs block immune-regulatory targets, they can lead to enhanced activation of immune system resulting in immune-related adverse events. Autoimmune encephalitis is a rare immune-related adverse event associated with immune checkpoint inhibitors. The incidence of autoimmune encephalitis is higher with combination or sequential CTLA-4 (ipilimumab) and PD1(nivolumab) inhibitor therapy than with monotherapy. With more widespread use of immunotherapy, it is important for clinicians to be aware of this rare and reversible cause of encephalitis. Early recognition and prompt initiation of immunosuppressive therapy with glucocorticoids is essential to enhance neurological recovery.

Keywords

Encephalitis / Immune related adverse effects / Immune checkpoint inhibitor / Nivolumab / Ipilimumab

References

[1] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 2012; 12(4): 252-264. PMid:22437870. https://doi.org/10.1038/nrc3239

[2] Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. International Immunopharmacology. 2018; 62: 29-39. PMid:29990692. https://doi.org/10.1016/j.intimp.2018.06.001

[3] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. The New England Journal of Medicine. 2018; 378(2): 158-168. PMid:29320654. https://doi.org/10.1056/NEJMra1703481

[4] Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti- PD-L1 immune checkpoint antibodies. Annals of Oncology. 2015; 26(12): 2375-2391. PMid:26371282. https://doi.org/10.1093/annonc/mdv383

[5] Blackmon JT, Viator TM, Conry RM. Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromedicine. 2015; 1(4): 39-45. https://doi.org/10.29245/2572.942X/2016/4.1040

[6] Spain L, Walls G, Julve M, et al. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Annals of Oncology. 2016; mdw558. PMid:28426103. https://doi.org/10.1093/annonc/mdw558

[7] Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer. 2015; 73: 1-8. PMid:28064139. https://doi.org/10.1016/j.ejca.2016.12.001

[8] Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016; 2(10): 1346-1353. PMid:27367787. https://doi.org/10.1001/jamaoncol.2016.1051

[9] Vogrig A, Muñiz-Castrillo S, Joubert B, et al. Central nervous system complications associated with immune checkpoint inhibitors. Journal of Neurology, Neurosurgery & Psychiatry. 2020; 91: 772-778. PMid:32312871. https://doi.org/10.1136/jnnp-2020-323055

[10] Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016; 73(8): 928e33. PMid:27271951. https://doi.org/10.1001/jamaneurol.2016.1399

[11] Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol. 2016; 29(6): 806-12. PMid:27653290. https://doi.org/10.1097/WCO.0000000000000391

[12] Manousakis G, Koch J, Sommerville RB, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013; 48(3): 440-444. PMid:23447136. https://doi.org/10.1002/mus.23830

[13] Thibult ML, Mamessier E, Gertner-Dardenne J, et al. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013; 25(2): 129-137. PMid:23087177. https://doi.org/10.1093/intimm/dxs098

[14] Guan H, Wan Y, Lan J, et al. PD-L 1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. Sci Rep. 2016. PMid:27762298. https://doi.org/10.1038/srep35651

[15] Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36: 1714-1768. PMid:29442540. https://doi.org/10.1200/JCO.2017.77.6385

[16] Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.